Phase I Study of Pazopanib Plus TH-302 in Advanced Solid Tumors

Richard F. Riedel,Kellen L. Meadows,Paula H. Lee,Michael A. Morse,Hope E. Uronis,Gerard C. Blobe,Daniel J. George,Jeffrey Crawford,Donna Niedzwiecki,Christel N. Rushing,Christy C. Arrowood,Herbert I. Hurwitz

Cancer chemotherapy and pharmacology（2017）

引用 9|浏览0

暂无评分

摘要

To define the maximum tolerated dose (MTD), recommended phase II dose (RPTD), and assess safety and tolerability for the combination of pazopanib plus TH-302, an investigational hypoxia-activated prodrug (HAP), in adult patients with advanced solid tumors.

查看译文

关键词

Pazopanib,TH-302,Advanced cancer,Phase I,Hypoxia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要